| c-Met is a receptor tyrosine kinase which regulates cancer cell growth, survival, angiogenesis, invasion, and metastases. c-Met is an emerging drug target, because through it, multiple therapeutic mechanisms of action are interdicted. |
|
| Xcovery is developing a small molecule inhibitor of the c-Met kinase. The Xcovery c-Met program is based on proprietary chemical IP. |
|
| |
|